BGM Group (BGM) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tonix Pharmaceuticals (TNXP) has outperformed BGM Group (BGM) over the past year, losing 67.2% versus a loss of 96.8%. Over five years, BGM leads with a -98.4% price change compared with -100.0% for TNXP. BGM Group is the larger company by market cap ($133.0 million vs $124.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | TNXP |
|---|---|---|
| Share price | $9.96 | $7.28 |
| Market cap | $133.01M | $124.86M |
| 1-day change | +6.07% | -3.58% |
| YTD return | -91.52% | -51.66% |
| 1-year return | -96.77% | -67.17% |
| 5-year return | -98.42% | -100.00% |
| EPS (TTM) | $-4.80 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $23.06 |
| 52-week low | $6.45 | $7.16 |
| Distance from 52-week high | -96.71% | -68.43% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +511.26% |
| Average volume | 6.13K | 537.49K |
| Shares outstanding | 12.69M | 17.15M |
| Employees | — | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNXP has outperformed BGM by 29.6 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
BGM vs TNXP FAQ
Which is bigger, BGM Group or Tonix Pharmaceuticals?
BGM Group (BGM) is larger, with a market capitalization of $133.01M compared with $124.86M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, BGM or TNXP?
TNXP returned -67.17% over the past 12 months, compared with -96.77% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.